Rosiglitazone and Cardiovascular Risk
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
In this issue of the Journal,
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Cited by
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetes Care · doi:10.2337/dc06-9912 · Cited by 1,203
DEPARTMENT OF HEALTH & HUMAN SERVICES
Schuchat, A. (2015) · Pharmacy Today · doi:10.1016/s1042-0991(15)32122-8 · Cited by 1,098
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
“The putative 30–40% relative increase in risk of myocardial infarctions is based on data that are widely viewed as less than definitive; still, these data have led to the recommendation that clinicians exercise increased caution in prescribing rosiglitazone [7–10].”
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Metabolic Mechanisms in Heart Failure
Ashrafian, H., Frenneaux, M. P., & Opie, L. H. (2007) · Circulation · doi:10.1161/circulationaha.107.702795 · Cited by 521
Meta-analysis: Its strengths and limitations
WALKER, E., HERNANDEZ, A. V., & KATTAN, M. W. (2008) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75.6.431 · Cited by 519
Reporting bias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010) · Trials · doi:10.1186/1745-6215-11-37 · Cited by 452
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2008) · Diabetes Care · doi:10.2337/dc08-9016 · Cited by 326
Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature
Duan, S. Z., Usher, M. G., & Mortensen, R. M. (2008) · Circulation Research · doi:10.1161/circresaha.107.164384 · Cited by 263
Kung, J., & Henry, R. R. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.691963 · Cited by 198
The Role of Mitochondria in the Pathophysiology of Skeletal Muscle Insulin Resistance
Pagel-Langenickel, I., Bao, J., Pang, L., & Sack, M. N. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0003 · Cited by 154
Rosiglitazone and cardiotoxicity –weighing the evidence
Nathan, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejme078117 · Cited by 126
Rosiglitazone and Risk of Cancer
Monami, M., Lamanna, C., Marchionni, N., & Mannucci, E. (2008) · Diabetes Care · doi:10.2337/dc07-2308 · Cited by 97
The 'forgotten' bile acid sequestrants: is now a good time to remember?
Bays, H. E., & Goldberg, R. B. (2007) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31815a69fc · Cited by 83
American Diabetes Association Indications for Statins in Diabetes
Eldor, R., & Raz, I. (2009) · Diabetes Care · doi:10.2337/dc09-s345 · Cited by 71
Savoia, C., Ebrahimian, T., Lemarié, C. A., Paradis, P., Iglarz, M., Amiri, F., Javeshgani, D., & Schiffrin, E. L. (2010) · Clinical Science · doi:10.1042/cs20090289 · Cited by 15
Metadata
- Authors
- Psaty, B. M., & Furberg, C. D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-14
- Volume
- 356
- Issue
- 24
- Pages
- 2522-2524
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149460582
- Cited by
- 178
- References
- 4
- FWCI
- 27.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.